NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

MaxCyte, Inc. (MXCT) Stock Analysis

MaxCyte, Inc. (MXCT) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

MXCT

$1.28

+$0.02 (+1.59%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MXCT with… →

MXCT Key Statistics

As of Sep 4, 2026
Trading
Open
$1.25
Previous Close
$1.26
Day's Range
1.25–1.30
52-Week Range
0.64–1.87
Volume
333.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.53
Valuation
Market Cap
$132.10M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.25
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.35
Financials (FY)
Revenue (FY)
$33.03M−14.50%
Net Income (FY)
−$44.63M
Profit marginThe share of revenue left as profit after all costs and taxes.
−114.77%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
103.21M
1-Year Return
−5.88%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
1.09M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MXCT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−17.42%
2025−62.74%
2024−11.49%
2023−13.92%
2022−46.42%
2021 (partial year)−40.06%

As of September 4, 2026.

MXCT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$33.03M−$44.63M−135.1%
2024$38.63M−$41.06M−106.3%
2023$41.29M−$37.92M−91.8%
2022$44.26M−$23.57M−53.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$33.03M$26.80M−$45.29M−$44.63M−135.1%
2024$38.63M$31.53M−$51.20M−$41.06M−106.3%
2023$41.29M$36.55M−$48.30M−$37.92M−91.8%
2022$44.26M$39.16M−$27.36M−$23.57M−53.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MXCT Valuation vs Medical Devices Median

Median of 151 stocks
MetricMXCTMedical Devices medianvs median
P/S ratio4.252.9843% above
Profit margin−114.77%−1.69%113.1 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

MaxCyte, Inc. (MXCT) is capitalised at $132.10M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 91.

The 52-week range on file runs from $0.64 to $1.87. MXCT last closed at $1.28 on September 4, 2026. That is +$0.02 (+1.59%) against the previous close. The latest close sits 99.07% above that 52-week low.

Financial Health

In fiscal 2025, MaxCyte, Inc. reported revenue of $33.03M. Against the prior fiscal year total of $38.63M, that is a change of −14.50%. The same year closed with a net loss of $44.63M. The reported profit margin is −114.77%. That is 113.1 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.35.

Across the 4 fiscal years on file, revenue moves from $44.26M in 2022 to $33.03M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 4.25 times revenue. On price-to-sales that is 42.95% above the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Over the trailing twelve months the price has returned −5.88%. Measured over 5 years, that is −40.52% a year compounded. Beta against the wider market is reported at 1.53. Annualized volatility over the trailing 5 years is 68.42%.

Growth & Income

No dividend is on file for MXCT.

The strongest complete calendar year on file is 2024 at −11.49%; the weakest is 2025 at −62.74%. Of the 4 complete calendar years on file, 0 finished higher. So far in 2026 the price is −17.42%.

Peer Comparison

MaxCyte, Inc. (MXCT) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MaxCyte, Inc. MXCT $132.10M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. MaxCyte, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About MaxCyte, Inc.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Visit website →